Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Lipocine, Inc. (NASDAQ: LPCN) shares fell 78.27% to $2.01 after the company announced that its LPCN 1154 treatment for postpartum depression failed to meet its primary endpoint in a Phase 3 trial, showing no statistically significant reduction in HAM-D17 scores compared to placebo. Despite this, a post hoc analysis indicated some positive results in participants with a history of psychiatric conditions. The treatment was well tolerated, and Lipocine has applied for breakthrough therapy and Fast Track designations for LPCN 1154.